| |
|
Headlines:
|
 |
Back
to index
Cisplatin - cyclophosphamide regimen
Abstract: Cyclophosphamide plus cis-platinum in combination: treatment
program for stage III or IV ovarian carcinoma.
A randomized prospective comparison of treatment with cyclophosphamide
and that with cyclophosphamide and cisplatinum, each in 21 patients with
advanced ovarian cancer, has shown that the time to progression of tumor
and the duration of survival were markedly improved in the patients receiving
the combination chemotherapy. Cytoreductive surgery was performed in most
of the patients in the study before the chemotherapy regimen was initiated.
Second-look surgery was performed after a year of chemotherapy. The chemotherapy
was administered on an outpatient basis, without excessive toxicity. At
2 years, 52.4% of the patients receiving
combination therapy had no progression of tumor, whereas 9.5% had no progression
of tumor in the group of patients receiving a single alkylating agent. Survival
at 2 years was 61.9% for the combination
chemotherapy group and 19.0% for those treated with cyclophosphamide alone.
The study demonstrates a striking superiority of combination chemotherapy
over single-agent chemotherapy in patients with advanced ovarian cancer.
References
Decker DG, Fleming TR, Malkasian GD Jr, Webb MJ, Jeffries JA, Edmonson
JH. Cyclophosphamide plus cis-platinum in combination: treatment program
for stage III or IV ovarian carcinoma. Obstet Gynecol. 1982 Oct;60(4):481-7.
|
|
|
|
Are you a doctor or a nurse?
Do you want to join the Doctors Lounge online medical community?
Participate in editorial activities (publish, peer review, edit) and
give a helping hand to the largest online community of patients.
Click on the link below to see the requirements:
Doctors Lounge Membership
Application |
|
| Regimen |
|
| Original regimen as described
by Decker: Cyclophosphamide....... 1000 mg / M2 IV day 1
Cisplatin....... 50 mg / M2 IV day 1
FREQUENCY 21 days
Decker DG et al. Obstet
Gynecol. 1982 Oct;60(4):481-7.
More recent regimens:
Cyclophosphamide....... 600 mg / M2 IV day 1
Cisplatin....... 100 mg / M2 IV day 1
FREQUENCY 21 days
Alberts et al. J Clin
Oncol 1992; 10:706 - 717.
Cyclophosphamide....... 750 mg / M2 IV day 1
Cisplatin....... 75 mg / M2 IV day 1
FREQUENCY every 21 days
McGuire et al. NEJM 1996; 334:1
- 6.
|
|
|
| |
|
|
| |
Summary |
Cisplatin
- cyclophosphamide vs. cyclophosphamide in stage III & IV ovarian cancer. |
| |
Progression
Free Survival |
@ 2 years 52.4% v. 9.5% |
| |
Overall Survival |
@ 2 years 61.9% v. 19.0%. |
| |
|
|
|
|
send
to a friend
printer
friendly version
